In This Article:
As the U.S. stock market navigates through a period of volatility marked by tariff announcements and tech sector selloffs, investors are keenly observing economic indicators for signs of potential recessionary pressures. Amidst this backdrop, stocks with high insider ownership often attract attention as they can signal confidence from those closest to the company's operations and strategy. In today's market environment, such insider stakes might suggest resilience and growth potential in uncertain times.
Top 10 Growth Companies With High Insider Ownership In The United States
| Name | Insider Ownership | Earnings Growth |
| Super Micro Computer (NasdaqGS:SMCI) | 14.2% | 29.8% |
| Duolingo (NasdaqGS:DUOL) | 14.4% | 37.1% |
| Hims & Hers Health (NYSE:HIMS) | 13.2% | 21.8% |
| Corcept Therapeutics (NasdaqCM:CORT) | 11.7% | 36.7% |
| Coastal Financial (NasdaqGS:CCB) | 14.5% | 46.3% |
| Astera Labs (NasdaqGS:ALAB) | 15.9% | 61.3% |
| BBB Foods (NYSE:TBBB) | 16.2% | 41.1% |
| Clene (NasdaqCM:CLNN) | 20% | 63.1% |
| Upstart Holdings (NasdaqGS:UPST) | 12.7% | 100.1% |
| Credit Acceptance (NasdaqGS:CACC) | 14.4% | 33.6% |
Let's dive into some prime choices out of the screener.
Harrow
Simply Wall St Growth Rating: ★★★★★☆
Overview: Harrow, Inc. is an eyecare pharmaceutical company focused on the discovery, development, and commercialization of ophthalmic products, with a market cap of approximately $1.03 billion.
Operations: The company's revenue segments include $133.22 million from the discovery, development, and commercialization of innovative ophthalmic therapies, with a segment adjustment of $35.92 million.
Insider Ownership: 13.3%
Harrow is experiencing significant growth, with revenue projected to increase by 36.4% annually, outpacing the broader US market. The company recently secured CMS approval for TRIESENCE, enhancing reimbursement prospects and potentially boosting revenue streams. Despite a delay in SEC filings, Harrow's strategic initiatives like VEVYE Access for All aim to improve product accessibility and affordability. The addition of Amir H. Shojaei as Chief Scientific Officer strengthens its leadership team amid expectations of profitability within three years.
-
Click here to discover the nuances of Harrow with our detailed analytical future growth report.
-
The valuation report we've compiled suggests that Harrow's current price could be quite moderate.
Lifeway Foods
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Lifeway Foods, Inc. produces and markets probiotic-based products in the United States and internationally, with a market cap of approximately $372.48 million.